ANLN antisense oligonucleotides and their applications

By designing antisense oligonucleotides targeting exon 9 of ANLN to interfere with the binding of SRSF2 to ANLN pre-mRNA, the problem of limited inhibitory effects of ASO drugs on breast cancer cell migration and metastasis in existing technologies has been solved, and effective inhibition of breast cancer cells has been achieved.

CN116875598BActive Publication Date: 2026-11-10JINAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310843493.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-07-11
Publication Date
2026-11-10
Estimated Expiration
2043-07-11

AI Technical Summary

Technical Problem

Existing ASO drugs are mainly used to degrade mRNA in various solid tumors, which may affect the patient's normal physiological activities, and have limited inhibitory effects on breast cancer cell migration and metastasis.

Method used

We designed antisense oligonucleotides targeting alternative splicing of ANLN exon 9 to regulate ANLN gene expression by interfering with the binding of SRSF2 to ANLN pre-mRNA, thereby inhibiting the generation of ANLN-L isoforms and reducing the invasive and migratory ability of breast cancer cells.

Benefits of technology

It effectively inhibits the scratch healing and migration ability of breast cancer cells, significantly reduces the invasive and metastatic potential of breast cancer cells, and has no toxic effects on cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116875598B_ABST
    Figure CN116875598B_ABST
Patent Text Reader

Abstract

This invention provides an ANLN antisense oligonucleotide, which is an antisense oligonucleotide targeting the core sequence "AAGAGAGGACAGGUGUUCAGGGAGGGGU" located on intron 8 and regulating alternative splicing in exon 9 of ANLN. ASO-ANLN can effectively inhibit the rate of scratch healing in breast cancer cells and suppress their invasion and migration. ASO-ANLN can inhibit the production of ANLN-L by inhibiting the binding of SRSF2 to ANLN pre-mRNA, thereby inhibiting breast cancer cell metastasis, and has almost no toxic effects on normal cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedicine, and in particular to an ANLN antisense oligonucleotide and its applications. Background Technology

[0002] ANLNs, as multidomain proteins, were initially recognized for their role in cell division. However, recent studies have shown that in various solid tumors, such as breast cancer, ANLNs can regulate breast cancer cell migration by modulating ECM adhesion or JNK signaling pathways and downregulating the expression of cell-cell adhesion-related genes. In addition to these effects, ANLNs may also influence cancer progression by affecting cancer metabolism, regulating the tumor microenvironment, and influencing angiogenesis and the cell cycle. These existing studies sufficiently demonstrate that ANLNs play a crucial role in tumorigenesis and development, particularly in tumor metastasis.

[0003] Since the launch of Vitravene, the first small nucleic acid drug, the small nucleic acid industry has developed for 20 years, with numerous small nucleic acid drugs approved and achieving some commercial success. Among them, antisense nucleic acid (ASO) drugs have attracted widespread attention due to their relatively small size, low hydrophilicity, high biocompatibility, strong specificity, and the ability to directly enter cells via endocytosis. With the successful launch of the ASO drug Nusinersen, research has begun on the application of antisense nucleic acid drugs in cancer development and progression. However, current research on the application of ASO drugs in various solid tumors mainly focuses on the mechanism of mRNA degradation. Since the expression of these mRNAs is also essential for normal physiological activities, this approach may, to some extent, affect the patient's normal physiological functions. Summary of the Invention

[0004] The main objective of this invention is to provide an ANLN antisense oligonucleotide, which is an antisense oligonucleotide that targets the core sequence “AAGAGAGGACAGGUGUUCAGGGAGGGGU” of the ANLN exon 9 alternative splicing SRSF2 located on exon 8 of ANLN.

[0005] Another object of the present invention is to provide applications of the above-mentioned antisense oligonucleotides.

[0006] An ANLN antisense oligonucleotide is at least one of the following:

[0007] ASO-ANLN-1, its nucleotide sequence is CCCTGAACACCTGTCCTCTCT;

[0008] ASO-ANLN-2, its nucleotide sequence is CACCTGTCCTCTCTTAACCCA;

[0009] ASO-ANLN-3, its nucleotide sequence is GTGTTTCAAAAACTCAGTCAC;

[0010] Or analogues of ASO-ANLN-1, ASO-ANLN-2, and ASO-ANLN-3 obtained by base insertion, deletion, or substitution, which still have the function of targeting SRSF2 to regulate the core sequence "AAGAGAGGACAGGUGUUCAGGGAGGGGU" contained in exon 9 of ANLN.

[0011] The application of the aforementioned ANLN antisense oligonucleotide in regulating ANLN gene expression.

[0012] The application of the aforementioned ANLN antisense oligonucleotide in regulating alternative splicing of ANLN exon 9.

[0013] The application of the aforementioned ANLN antisense oligonucleotide in the preparation of ANLN protein expression inhibitors.

[0014] The application of the aforementioned ANLN antisense oligonucleotide in inhibiting the invasion and migration of breast cancer cells.

[0015] The application of the aforementioned ANLN antisense oligonucleotide in the preparation of antitumor and / or antitumor metastasis drugs.

[0016] The tumor in question is breast cancer.

[0017] The present invention has the following advantages and effects compared with the prior art:

[0018] 1. The inventors previously analyzed the TCGA and HμManProteinAtlas databases and found that ANLN mRNA and protein expression were significantly upregulated in breast cancer samples, and that this upregulation was a marker of poor prognosis in breast cancer patients. Subsequently, RT-PCR was used to further investigate ANLN expression in MDA-MB-231 (triple negative) and MDA-MB-453 (HER2-positive) breast cancer samples. + ANLN mRNAs with exon 9 alternative splicing were found in both α and β-McF-7 (LμMinal type). The splice isoform of full-length ANLN containing exon 9 (ANLN-L) was upregulated in highly metastatic breast cancer cells, while the splice isoform of ANLN with exon 9 skipping (ANLN-S) was downregulated in highly metastatic breast cancer cells. Upregulation of ANLN-L expression promotes the invasion and migration of breast cancer cells, and the inclusion of exon 9 is regulated by the splicing factor SRSF2. Therefore, the design of small nucleic acid drugs targeting the alternative splicing of ANLN exon 9 is of great significance for the treatment of metastatic breast cancer.

[0019] 2. Compared with ASO-ANLN-3, ASO-ANLN-1 and ASO-ANLN-2 can more effectively inhibit the speed of scratch healing in breast cancer cells.

[0020] 3. Compared with ASO-ANLN-3, ASO-ANLN-1 and ASO-ANLN-2 can more effectively inhibit the invasion and migration of breast cancer cells.

[0021] 4. Compared with ASO-ANLN-3, which targets exon 8 of ANLN, ASO-ANLN-1 and ASO-ANLN-2, which target intron 8 of ANLN pre-mRNA, can interfere with the binding of SRSF2 to ANLN pre-mRNA, better inhibit the inclusion of exon 9 of ANLN, and more effectively reduce the generation of ANLN-L isoforms that promote breast cancer metastasis.

[0022] 5. ASO-ANLN-1 and ASO-ANLN-2 have almost no toxic effects on cells. Attached Figure Description

[0023] Figure 1 This is a graph showing the results of RT-qPCR screening for effective concentrations of antisense nucleic acids.

[0024] Figure 2 This is a graph showing the results of RT-qPCR detection of the effect of ASO on ANLN isomers.

[0025] Figure 3 This is a graph showing the effect of RIP experiment on the inhibitory effect of ASO on the binding of SRSF2 and ANLN pre-mRNA.

[0026] Figure 4 This is a graph showing the results of a cell scratch assay to detect the effect of optimal concentrations of ASO-ANLN-1, ASO-ANLN-2, and ASO-ANLN-3 on cell migration ability. A: MDA-MB-231 cells were transfected with ASO-ANLN-1 at concentrations of 0 nM, 500 nM, and 1 μM; ASO-ANLN-2 at concentrations of 0 nM, 50 nM, and 100 nM; and ASO-ANLN-3 at concentrations of 0 nM and 1 μM. After 48 h, the cells were digested and seeded into 6-well plates, and scratch healing was assessed at 48 h. B: Quantitative analysis of scratch healing rate. Data are expressed as mean ± SD (N=3). Tukey's test for one-way ANOVA was used to determine statistical significance between groups. "*" indicates P < 0.05 compared to 0 nM, and "**" indicates P < 0.01 compared to 0 nM. Data are expressed as mean ± SD (N = 3), the magnification of the graph is 100×, and the scale bar length is 200μm.

[0027] Figure 5This is a Transwell assay showing the effect of optimal concentrations of ASO-ANLN-1, ASO-ANLN-2, and ASO-ANLN-3 on cell invasion and migration. A: MDA-MB-231 cells were transfected with 1 μM ASO-ANLN-1, 100 nM ASO-ANLN-2, and 1 μM ASO-ANLN-3. After 48 h, the cells were digested and seeded at 5 × 10⁶ cells per cell line. 4 A: Cells were transferred to the upper chamber of a Transwell without matrix gel coating. After 48 hours, the number of cells in the lower layer was observed by crystal violet staining. B: MDA-MB-231 cells were transfected with ASO-ANLN-1 at a concentration of 1 μM, ASO-ANLN-2 at 100 nM, and ASO-ANLN-3 at 1 μM. After 48 hours, the cells were digested and seeded at a concentration of 5 × 10⁶ cells / year. 4 Cells were placed in the upper chamber of a Transwell containing matrix gel, and the number of cells in the lower layer was observed after 48 hours by crystal violet staining. Data are expressed as mean ± SD (N=3). Tukey's test of one-way ANOVA was used to determine statistical significance between groups. "***" indicates P < 0.001 compared to 0 nM. The magnification of the figure is 100×, and the scale bar is 200 μm.

[0028] Figure 6 This is a graph showing the results of the RNA pull-down assay to detect the effect of ASO on the binding of SRSF2 to the ANLN core binding sequence. Detailed Implementation

[0029] The present invention will be further described in detail below with reference to the embodiments and accompanying drawings, but the embodiments of the present invention are not limited thereto.

[0030] Unless otherwise specified in the following implementation plan, the test conditions are generally as per standard test conditions or the test conditions recommended by the reagent company. Unless otherwise specified, all materials and reagents used are commercially available.

[0031] Example 1: Design of ANLN antisense oligonucleotide active sequence and preparation of transfection reagent

[0032] I. Design of ANLN antisense oligonucleotide sequences

[0033] Previous studies by our research group have found that SRSF2 can bind to the "AG"-rich sequence in intron 8 of ANLN pre-mRNA, thereby promoting ANLN exon 9 inclusion and promoting the invasion and migration of breast cancer cells. The binding regulatory sequence is: "AAGAGAGGACAGGUGUUCAGGGAGGGGU".

[0034] ASO-ANLN-1 and ASO-ANLN-2 were designed to target this core sequence to interfere with the binding of SRSF2 to ANLN pre-mRNA, thereby regulating alternative splicing of ANLN exon 9. ASO-ANLN-3 was designed to target ANLN exon 8, mainly through the mechanism of mRNA degradation.

[0035] ASO-ANLN-1:5'-CCCTGAACACCTGTCCTCTCT-3';

[0036] ASO-ANLN-2:5'-CACCTGTCCTCTCTTAACCCA-3';

[0037] ASO-ANLN-3:5'-GTGTTTCAAAAACTCAGTCAC-3';

[0038] A random, disordered sequence was selected as a control group, which was verified by BLAST to not target human gene sequences.

[0039] ASO-ANLN-Control:5'-CCTAAGGTTAAGTCGCCCTCG-3'.

[0040] Example 2: Oligonucleotide Cell Transfection Experiment

[0041] 1. Preparation of ANLN antisense oligonucleotide transfection reagent

[0042] (1) The designed and synthesized antisense nucleic acid was sent to Qingke Biotechnology Co., Ltd. to synthesize antisense nucleic acid dry powder, which was prepared into 100μM with RNase-free water and dispensed for use.

[0043] (2) Prepare antisense nucleic acid transfection complexes of various concentrations according to the table below, and incubate at room temperature for 5 min;

[0044] Table 1 Antisense Nucleic Acid Transfection Reagents

[0045]

[0046] (3) Add the antisense nucleic acid-liposome mixture, mix slowly, and incubate for 48 hours to obtain ASO-ANLN storage solutions of different concentrations.

[0047] 2. Cell transfection experiment

[0048] (1) Inoculate an appropriate amount of MDA-MB-231 cells into a 10cm cell culture dish. After the cells have covered 60-70% of the bottom of the culture dish, remove the culture medium, wash the cells twice with PBS, and replace with 10ml of fresh DMEM culture medium.

[0049] (2) Place 750 μL of serum-free and antibiotic-free DMEM medium and different concentrations of ASO-ANLN stock solution prepared in Example 1 into a clean 1.5 mL centrifuge tube and incubate at room temperature for 10 min. Add the incubated ASO-plasmid liposome mixture evenly into the cells and culture for 48 h.

[0050] Example 3: Real-time quantitative PCR (RT-qPCR) detection of the effects of ANLN antisense oligonucleotides on gene expression.

[0051] 1. Extraction of cellular RNA:

[0052] (1) After transfection in Example 1, the culture medium in the cell culture dish was removed by pipetting. After washing twice with PBS buffer, 400 μl of Trizol lysis buffer was added to the cell culture dish, fully covered and allowed to stand for 10 min. Then the Trizol lysis buffer was transferred to a 1.5 mL EP tube without RNase.

[0053] (2) Add 80 μL of chloroform to the EP tube, then quickly invert the centrifuge tube for 15 seconds. Place the centrifuge tube in an ice box and let it stand for 10 minutes, then centrifuge at 12,000 rpm at 4°C for 10 minutes. After centrifugation, slightly tilt the tube and aspirate the supernatant liquid into a 1.5 mL RNase-free centrifuge tube.

[0054] (3) Add 500 μL of isopropanol (pre-cooled at 4℃) to the centrifuge tube, invert and shake 10 times, then let the centrifuge tube stand in an ice box for 10 min, and then centrifuge the centrifuge tube at 12000 rpm and 4℃ for 10 min. After centrifugation, discard the supernatant.

[0055] (4) Add 1 mL of washing buffer (75% ethanol + 25% DEPC water) to the centrifuge tube above. Use a pipette to carefully blow the RNA at the bottom of the tube. After washing thoroughly, centrifuge at 12000 rpm and 4℃ for 15 min. After centrifugation, discard the washing buffer. After washing twice, place the centrifuge tube upside down on filter paper in a clean bench and ventilate to remove the residual washing buffer.

[0056] (5) Finally, add 30 μL of DEPC water to a centrifuge tube to fully dissolve the RNA. Then, pipette 1 μL of the RNA to be tested into a micro spectrophotometer to detect its concentration and purity. After the test, the obtained RNA is used for reverse transcription or stored in an ultra-low temperature freezer for subsequent experiments.

[0057] 2. Reverse transcription

[0058] The RNA was reverse transcribed according to the instructions in the "HifairTMII 1st Strand cDNA Synthesis Kit" of Shanghai Yisheng Biotechnology Co., Ltd.

[0059] Table 2 Reverse Transcription System

[0060]

[0061]

[0062] The reverse transcription system was incubated at 37°C for 15 minutes and then at 85°C for 5 seconds (enzyme inactivation) to complete the reverse transcription and obtain cDNA.

[0063] 3. RT-PCR detection of differences in ANLN isoform mRNA levels

[0064] Prepare the RT-PCR reaction solution according to Table 3 and perform the RT-PCR reaction according to the procedure in Table 4. After the RT-PCR reaction, perform agarose gel electrophoresis on the products. After electrophoresis, take pictures using a gel imaging system and analyze the band grayscale using ImageJ. Calculate the skipping rate of exon 9 of ANLN using the following formula:

[0065] ANLN exon skipping rate = (short isomer gray value / (long isomer gray value + short isomer gray value)) × 100%.

[0066] Table 3 RT-PCR reaction solution

[0067]

[0068] Table 4 RT-PCR Primer Sequences

[0069]

[0070] Table 5 RT-PCR reaction procedure

[0071]

[0072]

[0073] 4. RT-qPCR detection of differences in ANLN isoform mRNA levels

[0074] The above cDNA was subjected to RT-qPCR reaction according to the instructions in the "Hieff RT-qPCR SYBR Green Master Mix" from Shanghai Yisheng. The RT-qPCR system was added to white opaque eight-tube tubing (operated on ice in the dark, three replicates per gene). The RT-qPCR system and conditions are as follows, and the primers used in the RT-qPCR experiment are:

[0075] ANLN-L-FP: 5'-TTCAAAAACTCAGTCACTTCCA-3';

[0076] ANLN-L-RP: 5'-TAGATTTCGTCATTTCGCATTC-3';

[0077] ANLN-S-FP: 5'-TTCAAAAACTCAGTCACTTCCA-3';

[0078] ANLN-S-RP: 5'-TCACGTATCACTTCTTTAGGTTTCTG-3'.

[0079] Table 6 RT-qPCR reaction system

[0080]

[0081] Table 7 RT-qPCR reaction conditions

[0082]

[0083] After the RT-qPCR reaction is complete, and after ensuring that the RT-qPCR amplification curve and melting curve are normal, proceed according to step 2. -ΔΔCt The method is used for relative quantitative analysis, where ΔΔCt=[Ct(experimental group-target gene)-Ct(experimental group-internal reference gene)]-[Ct(control group-target gene-Ct(control group-internal reference gene)].

[0084] Example 4: RNA-binding protein immunoprecipitation (RIP) experiment using ANLN antisense oligonucleotides

[0085] 1. Antisense nucleic acid transfection

[0086] (1) Inoculate 9×10 cells into a 6cm cell culture dish. 6 MDA-MB-231 cells were cultured until they covered 70% of the culture dish surface. The culture medium was removed, the cells were washed twice with PBS, and then replaced with 3 ml of DMEM medium containing 10% FBS without antibiotics.

[0087] (2) Prepare antisense nucleic acid transfection complexes of various concentrations according to the table below, incubate at room temperature for 5 min, and add to a 6 cm culture dish;

[0088] Table 8 Antisense Nucleic Acid Transfection Reagents

[0089]

[0090] 2. Extraction of total cell protein

[0091] After the cells in the cell culture dish have grown to basically cover the bottom of the cell culture, the culture medium is aspirated, the cells are washed twice with PBS, and then 1 ml of RIPA cell lysis buffer (with 1 mM PMSF protease inhibitor added before use) is added and the dish is placed on ice for 20 min to allow for complete lysis. After lysis, the cells are centrifuged at 13,000 rpm for 15 min at 4 °C. After centrifugation, the protein supernatant is transferred to a sterile 1.5 mL EP tube. The total protein can be used for subsequent experiments or stored in an ultra-low temperature freezer.

[0092] 3. Detection of cell protein concentration using the BCA method

[0093] Protein concentration was determined by the BCA colorimetric method: A standard curve was established using BSA standard proteins at concentrations of 0, 0.1, 0.2, 0.4, 0.6, 0.8, 1, and 2 mg / mL. 10 μL of the protein standard sample or test sample and 100 μL of BCA working solution were added to each well of a 96-well plate, with three replicates. The plates were incubated at 37°C for 30 min, and then the absorbance at 562 nm was measured using a microplate reader. After establishing the standard curve (R... 2 The target protein concentration was measured using a concentration of >0.99, and the total protein concentration in different groups was adjusted to be consistent.

[0094] 4. Immunoprecipitation of RNA-binding proteins

[0095] (1) Take 70 μL of protein G magnetic beads and wash them three times with antibody dilution buffer, each time for 10 min. Then add 5 μg of GFP antibody and incubate at 4 °C for 6 h. After incubation, add an appropriate amount of washing buffer and wash three times on a vertical suspension apparatus, each time for 10 min.

[0096] (2) After washing three times, 4 mg of the extracted protein was added to the GFP antibody-magnetic bead complex and incubated overnight at 4°C. After sufficient incubation, in order to remove the protein that did not bind to the antibody, an appropriate amount of washing buffer was added and the mixture was washed three times on a vertical suspension apparatus for 10 min each time.

[0097] (3) After thorough washing, centrifuge at low speed, remove the washing solution, add a certain amount of loading buffer, and heat at 100℃ for 10 min. Then, use Western blotting to detect the interference level of ASO-ANLN on the binding of SRSF2 and ANLN pre-mRNA.

[0098] 5. Western blot

[0099] (1) SDS-PAGE gel preparation: Prepare the lower gel (separating gel) according to the formula. Add 5 mL of the prepared lower gel to the gel casting machine, then add an appropriate amount of isopropanol to flatten the liquid surface. Let it stand at room temperature until the lower gel is completely solidified. Then, invert the gel casting machine to remove the upper layer of isopropanol and pour it out. Use filter paper to absorb the remaining liquid. Next, prepare the upper gel (staple gel) according to the formula. Add the upper gel to the gel casting machine. After filling it, insert the comb vertically. Let it stand at room temperature for 5 hours. It is then ready for subsequent SDS-PAGE electrophoresis.

[0100] (2) Denaturation of protein samples: The protein samples from different groups were adjusted to the same concentration using RIPA lysis buffer to ensure the same loading volume. An appropriate amount of protein loading buffer was added to the protein samples, and after thorough mixing, the samples were boiled in a 95°C water bath for 10 min to denature them. After cooling to room temperature, the samples were ready for subsequent SDS-PAGE detection.

[0101] (3) SDS-PAGE electrophoresis: Take 30 μg of proteins from different groups for SDS-PAGE vertical electrophoresis. Set the voltage to 80V. After the indicator bands have all entered the separating gel, increase the electrophoresis voltage to 120V and stop electrophoresis when the indicator bands leave the gel.

[0102] (4) Transfer: Activate the appropriately sized PVDF membrane in methanol for 5 minutes. Place the membrane in the electrophoresis clamp of the wet transfer apparatus in the following order: positive electrode, sponge pad, three layers of filter paper, activated PVDF membrane, electrophoresis gel, three layers of filter paper, sponge pad, and negative electrode. Align each layer squarely and remove any air bubbles in the center. Transfer at 200 mA for 120 minutes.

[0103] (5) Blocking: The PVDF membrane was washed with TBST to remove residual transfer solution components, and then blocked at room temperature for 2 hours in a 5% skim milk powder solution (diluted with TBST).

[0104] (6) Antibody incubation: After blocking is completed, add the corresponding primary antibody (diluted with blocking buffer according to the recommended dilution concentration in the instructions) and incubate overnight in a horizontal shaker at 4°C. After incubation, wash 4 times with TBST for 8 minutes each time, then add the corresponding secondary antibody (diluted with blocking buffer according to the recommended dilution concentration in the instructions) and incubate at room temperature in a horizontal shaker for 1.5 hours. After incubation, wash 4 times with TBST for 8 minutes each time.

[0105] (7) Development: Add fresh ECL luminescent solution evenly (prepare fresh for use) to fully cover the PVDF film, set the exposure mode to automatic exposure, and place the PVDF film in the GEAI600 chemiluminescence analyzer for imaging.

[0106] (8) Materials: Primary antibody: SRSF2 antibody (ab204916-40ul) (Abcam); Secondary antibody: ①HRP anti-rabbit IgG (A0208) (Beyotime)

[0107] Example 5: Scratch assay to detect the effect of antisense nucleic acids on the scratch healing ability of tumor cells

[0108] (1) According to 6×10 5 MDA-MB-231 cells were seeded in 6-well plates at a cell / well density and cultured in an incubator until confluence reached 60-70%. ASO-ANLN was transfected into MDA-MB-231 cells using different concentrations of ASO-ANLN stock solution prepared in Example 2. Cells were cultured until they covered 95% of the bottom of the 6-well plate, with 3 replicates per cell group.

[0109] (2) Remove the original culture medium, wash the cells three times with PBS, add 1 ml of PBS and use a 200 μL pipette tip to make a straight scratch on the bottom of the 6-well plate, then gently wash three times with PBS to remove the scraped cells.

[0110] (3) Add 2 mL of MDEM medium (without serum) to each well, observe and record the width W(0h) of the corresponding scratch in each well at 100× magnification under a microscope, and then incubate normally in an incubator.

[0111] (4) After 48 hours, observe and record the width W(48h) of the corresponding scratch in each hole at 100× magnification under a microscope, and calculate the experimental results using the following formula.

[0112] Scratch healing rate = W(0h) - W(48h) / W(0h)

[0113] Example 6: Transwell cell migration and invasion assay to detect the effect of antisense nucleic acids on cell viability

[0114] (1) According to 6×10 5 MDA-MB-231 cells were seeded in 6-well plates at a cell / well density and cultured in an incubator until confluence reached 60-70%. ASO-ANLN was transfected into MDA-MB-231 cells using different concentrations of ASO-ANLN stock solution prepared in Example 2. Cells were cultured until they covered 95% of the bottom of the 6-well plate, with 3 replicates per cell group.

[0115] (2) Mix the culture medium and basement membrane matrix (Matrigal) at a ratio of 8:1 to obtain the matrix gel. Then, add 70 μL of the mixed matrix gel to each Transwell chamber and place the Transwell chamber in a cell culture incubator for 2 hours. After the matrix gel has completely solidified, add 100 μL of culture medium to the upper chamber of the Transwell and 500 μL of culture medium to the lower chamber of the Transwell. Place the Transwell chamber in a cell culture incubator overnight for equilibration.

[0116] (3) Resuspend MDA-MB-231 cells from different groups in DMEM medium (serum-free), and take 200 μL of cell suspension (total 5 × 10⁻⁶ cells). 4 Add 1000 μL of DMEM medium containing 10% FBS to the upper chamber of the Transwell and add 500 μL of DMEM medium to the lower chamber.

[0117] (4) After 48 hours of normal culture, the Transwell chamber was removed and the matrix gel in the Transwell chamber and the cells in the upper membrane (non-permeable membrane) were gently wiped away with a medical cotton swab. Then the upper membrane was washed three times with PBS.

[0118] (5) Add 200 μL of 4% paraformaldehyde to the Transwell chamber and fix the cells at room temperature for 10 min. Then wash with PBS three times for 10 min each time.

[0119] (6) Add 200 μL of DAPI (working concentration 5 ng / mL) to the Transwell chamber, stain in the dark for 10 min, and then wash with PBS 3 times for 10 min each time.

[0120] (7) Observe the cells in the submural layer of the Transwell chamber under a fluorescence microscope at 100× magnification and use ImageJ software to calculate the number of cells in each field of view.

[0121] Example 7: RNApulldowm assay to detect the interference of antisense nucleic acids on the binding ability of SRSF2 binding regulatory sequences.

[0122] (1) The designed In 8-WT (AAGAGAGGACAGGUGUUCAGGGAGGGGU) sequence was sent to Qingke Biotechnology Co., Ltd. to synthesize a biotin-labeled RNA fragment at the 3' end. 4 μg of the biotin-labeled RNA fragment was heated at 60℃ for 10 min, and then allowed to cool naturally to 4℃.

[0123] (2) Prepare the washing solution and buffer solution required for RNA pulldown according to the table below.

[0124] Table 9RNA capture Buffer

[0125]

[0126] Table 10 Binding Buffer

[0127]

[0128] Table 11 Wash Buffer

[0129]

[0130] (3) Wash the streptolysin-labeled magnetic beads A three times with an appropriate amount of Washing Buffer in a vertical resuspender for 10 min each time. Then, resuspend the magnetic beads with 70 μL Capture Buffer, add 4 μg of RNA to restore secondary structure, and incubate in a vertical resuspender at 4 °C for 6 h.

[0131] (4) After sufficient incubation, in order to remove RNA that has not bound to the magnetic beads, wash the magnetic beads with an appropriate amount of washing solution in a vertical suspension apparatus for 10 min. Repeat this operation 3 times. Then add 10 μl protein-RNA binding buffer and 50 μl sterile 50% glycerol.

[0132] (5) Add 2 mg of extracted nuclear protein and different concentrations of ASO-ANLN, and incubate overnight at 4°C. After they are fully bound, wash three times with an appropriate amount of washing buffer in a vertical suspension apparatus, each time for 10 min, to remove unbound protein. After thorough washing, add an appropriate amount of loading buffer to the magnetic beads and heat at 100°C for 10 min. Then perform a Western blot experiment.

[0133] Experimental results

[0134] Conclusion 1: Compared with ASO-ANLN-3, ASO-ANLN-1 and ASO-ANLN-2, which interfere with alternative splicing, can more effectively affect the expression ratio of ANLN-S.

[0135] The RT-PCR results in Example 3 showed that, compared with the control group, 50 nM, 500 nM, and 1 μM ASO-ANLN-1 increased the proportion of the ANLN-S isomer, with the effect being greatest at 500 nM. Similarly, 50 nM, 100 nM, and 250 nM ASO-ANLN-2 also increased the proportion of the ANLN-S isomer, with the 50 nM concentration of ASO-ANLN-2 having the greatest effect. Figure 1 ASO-ANLN-3 only affects the expression ratio of ANLN-S at a concentration of 1 μM. Figure 1 ).

[0136] RT-qPCR results showed that 1 μM ASO-ANLN-1 increased the ANLN-S content in the ANLN isomer by 2.15-fold. 100 nM ASO-ANLN-2 increased the ANLN-S content in the ANLN isomer by 2.58-fold. Figure 2 ), while 1 μM ASO-ANLN-3 only increased the ANLN-S content by 1.44 times ( Figure 2 ).

[0137] Based on the combined results of RT-PCR and RT-qPCR, the optimal concentrations of ASO-ANLN-1 (1 μM) and ASO-ANLN-2 (100 nM) were determined.

[0138] Conclusion 2: ASO-ANLN-1 inhibits the binding of SRSF2 to ANLN pre-mRNA in a concentration-dependent manner. A certain concentration of ASO-ANLN-2 can also inhibit the binding of SRSF2 to ANLN pre-mRNA, but not in a concentration-dependent manner.

[0139] The RNA-binding protein immunoprecipitation experiment in Example 4 showed that ASO-ANLN-1 effectively inhibited the binding of SRSF2 to ANLN pre-mRNA starting from a concentration of 250 nM, and the inhibitory effect gradually increased with increasing concentration, with the most significant effect at 1 μM. ASO-ANLN-2 at certain concentrations could also inhibit the binding of SRSF2 to ANLN pre-mRNA, with the best inhibitory effects at 50 nM, 100 nM, and 250 nM. However, ASO-ANLN-2 did not inhibit the binding of SRSF2 to ANLN pre-mRNA in a concentration-dependent manner. Figure 3 ).

[0140] Conclusion 3: ASO-ANLN-1 and ASO-ANLN-2 can inhibit the migration and invasion of breast cancer cells.

[0141] In Example 5, ASO-ASO-1 (500 nM, 1 μM), ASO-ASO-2 (50 nM, 100 nM), and ASO-ANLN-3 (1 μM) were transfected into MDA-MB-231 cells, and the effects of ASO-ANLN were preliminarily explored through scratch healing experiments. The results showed that ASO-ANLN-1, ASO-ANLN-2, and ASO-ANLN-3 could all inhibit the scratch healing rate of breast cancer cells. However, compared with ASO-ANLN-3, ASO-ANLN-1 (1 μM) and ASO-ANLN-2 (100 nM) showed the highest inhibitory effect on the scratch healing efficiency of MDA-MB-231 cells at the optimal concentration. ASO-ANLN-3 (1 μM) reduced the scratch healing efficiency to 0.62 times that of the control group, while ASO-ANLN-1 (1 μM) and ASO-ANLN-2 (100 nM) reduced the scratch healing rate to 0.50 times and 0.60 times that of the control group, respectively. Figure 4 ).

[0142] Preliminary results from the scratch assay indicated that ASO-ANLN-1 and ASO-ANLN-2 had a stronger inhibitory effect on the scratch healing rate of MDA-MB-231 cells, with ASO-ANLN-1 (1 μM) and ASO-ANLN-2 (100 nM) showing the strongest inhibitory efficiency. Subsequently, in Example 6, ASO-ANLN-Control, ASO-ANLN-1 (1 μM), ASO-ANLN-2 (100 nM), and ASO-ANLN-3 (1 μM) were transfected into MDA-MB-231 cells. The inhibitory effect of ASO-ANLN on the migration and invasion of breast cancer cells was detected by transwell assay. Migration assay results showed that, compared with the control group, ASO-ANLN-1 (1 μM), ASO-ANLN-2 (100 nM), and ASO-ANLN-3 (1 μM) all inhibited the number of migrating breast cancer cells. Among them, ASO-ANLN-3 (1 μM) only reduced the number of migrating cells to 0.64 times that of the control group, while ASO-ANLN-1 (1 μM) and ASO-ANLN-2 (100 nM) reduced the number of migrating cells to 0.51 and 0.56 times that of the control group, respectively. Figure 5Therefore, at the optimal concentration, ASO-ANLN-1 and ASO-ANLN-2 exhibited stronger inhibitory effects on breast cancer cell migration compared to ASO-ANLN-3. Subsequently, invasion experiments were performed on ASO-ANLN-1 (1 μM) and ASO-ANLN-2 (100 nM) to detect the effect of ASO-ANLN on the invasive ability of breast cancer cells. The results showed that both ASO-ANLN-1 (1 μM) and ASO-ANLN-2 (100 nM) could inhibit the invasive ability of breast cancer cells, and ASO-ANLN-1 (1 μM) and ASO-ANLN-2 (100 nM) reduced the number of invasive breast cancer cells to 0.45 and 0.23 times that of the control group, respectively. Figure 5 ).

[0143] Conclusion 4: ASO-ANLN-1 and ASO-ANLN-2 can inhibit the invasion and migration of breast cancer cells by interfering with the binding of SRSF2 to ANLN pre-mRNA.

[0144] In Example 7, a biotin-labeled core binding fragment was co-incubated with streptavidin magnetic beads. After incubation, ASO-ANLN-1 (1 μM), ASO-ANLN-2 (100 nM), and 5 μg of MDA-MB-231 nuclear protein were added to the RNA-magnetic bead complex, and incubated overnight at 4°C. The binding ability of SRSF2 to the core RNA sequence was detected by RNA pulldown. The results showed that ASO-ANLN-1 (1 μM) and ASO-ANLN-2 (100 nM) could effectively inhibit the binding of SRSF2 to the core RNA sequence, and the effect of ASO-ANLN-1 (1 μM) was more significant. Figure 6 In summary, ASO-ANLN can inhibit the generation of ANLN-L by inhibiting the binding of SRSF2 to ANLN pre-mRNA, thereby inhibiting the metastasis of breast cancer cells.

[0145] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. An ANLN antisense oligonucleotide, characterized in that... It is at least one of the following: ASO-ANLN-1, its nucleotide sequence is CCCTGAACACCTGTCCTCTCT; ASO-ANLN-2 has the nucleotide sequence CACCTGTCCTCTCTTAACCCA.

2. The use of the ANLN antisense oligonucleotide according to claim 1 in the preparation of antitumor and / or antitumor metastasis drugs, characterized in that: The tumor in question is breast cancer.